Copy

Click here if you cannot read this message

  Press Release January 2015  
 
 
 

Bone Therapeutics Expands Product Portfolio with New Research into Innovative Combined Cell-Matrix Product

€1 million funding secured from the Walloon Region to investigate these innovative products for the treatment of large bone defects

Gosselies, Belgium, 5 January 2015 - BONE THERAPEUTICS, the regenerative therapy company addressing unmet medical needs in the fields of fracture repair and bone fracture prevention, today announces that it has begun a new research project to investigate novel combined osteoblastic cell-matrix products for the treatment of large bone defects. The government of the Walloon Region has granted the Company €1 million of non-dilutive funding, in the form of recoverable cash advances, to finance this project.

In the project entitled “MXB Bioprinting”, Bone Therapeutics will combine its allogeneic1 bone-forming (osteoblastic) cells within a 3-D bioprinted scaffold to treat large bone defects2 resulting from trauma, bone disease or surgical procedures such as bone metastasis resection. This innovative approach represents a compelling alternative to bone autograft, the current standard-of-care for large bone defects, which is associated with significant morbidities.

The cell-matrix scaffold will be tailored to the size and form of the bone defect and will be designed to mimic the natural bone in terms of shape, structure and biomechanical properties. Once implanted, the 3-D patient-tailored matrix is intended to be progressively replaced by natural bone tissue, produced by the off-the-shelf osteoblastic cells as well as by the ones from the patient that will have been recruited at the site. Furthermore, as achieving adequate vascularization can be problematic due to the size of these defects, the product is designed to mitigate against this risk. The cells in the matrix will also be designed to stimulate the formation of new blood vessels by releasing factors that recruit endothelial cells (which are involved in the formation of blood vessels) to the defect site.

Enrico Bastianelli, CEO of Bone Therapeutics commented: "This novel approach utilising our allogeneic bone-forming cells within a precisely patient tailored 3-D bioprinted structure could herald a new and highly effective treatment for large bone defects and success in a field where regenerative medicine was thought to be untenable. We are grateful to the Walloon region in supporting this important project."

1Allogeneic cells are derived from a healthy donor rather than from the patient itself.
2In this project, large bone defects are defined as bone defects larger than 2.5 cm.

 

 
 
 
 
 

Press Release & News

 
 

 
 

For further information, please contact:

Bone Therapeutics SA

Tel: +32 (0)2 529 59 90
Enrico Bastianelli, Chief Executive Officer
Wim Goemaere, Chief Financial Officer
info@bonetherapeutics.com

Consilium Strategic Communications

Amber Bielecka, Mary-Jane Elliott,
Jessica Hodgson and Lindsey Neville
Tel: +44 (0) 20 3709 5708
bonetherapeutics@consilium-comms.com

 
 

 
 
Follow us

Click here to unsubscribe
 
 
 
 

About Bone Therapeutics

Bone Therapeutics is a leading biotechnology company specializing in the development of innovative regenerative therapies for the repair and prevention of bone fractures. The current standard of care in this field involves major surgeries and long recovery periods. To overcome these problems, Bone Therapeutics is developing a range of innovative products containing regenerative osteoblastic/bone-forming cells, administrable via a minimally invasive percutaneous technique; a unique proposition in the market.
PREOB®, Bone Therapeutics’ autologous cell product, is currently in pivotal Phase III clinical studies for two indications: osteonecrosis and non-union fractures, and in Phase II for severe osteoporosis. ALLOB®, its allogeneic cell product, is in Phase II for the treatment of delayed-union fractures and lumbar fusion for degenerative disease of the spine. The Company also runs preclinical research programs and develops novel product candidates.
Founded in 2006, Bone Therapeutics is headquartered in Gosselies (South of Brussels, Belgium). Bone Therapeutics’ regenerative products are manufactured to the highest GMP standards and are protected by a rich IP estate covering 9 patent families. Further information is available at www.bonetherapeutics.com


Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company or, as appropriate, the Company directors' current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

 
Bone Therapeutics S.A. • Rue Adrienne Bolland, 8 • 6041 Gosselies • Belgium (Europe) • Phone: +32 (0) 2 529 59 90 • Fax: +32 (0) 2 529 59 93 • www.bonetherapeutics.com